Advertisement
Organisation › Details
Valbiotis S.A. (Euronext Growth: ALVAL)
VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agri-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These agreements enable it to benefit from a considerable leverage effect since it was set up thanks, in particular, to the experts and technical partners mobilized for these projects. VALBIOTIS is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. VALBIOTIS has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). *
Start | 2014-02-01 established | |
Industry | nutripharmaceutical | |
Industry 2 | Valedia® | |
Person | Peltier, Sébastien (Valbiotis 201803 Board Chairman) | |
Region | France_oo | |
Country | France | |
Street | 12F rue Paul Vatine | |
City | 17180 Périgny | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Valbiotis S.A.. (3/15/18). "Press Release: Valbiotis Obtains Strategic Patent for Valedia in the United States". La Rochelle. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Valbiotis S.A. (Euronext Growth: ALVAL)
- [1] Valbiotis S.A.. (3/15/18). "Press Release: Valbiotis Obtains Strategic Patent for Valedia in the United States". La Rochelle....
- [2] Valbiotis S.A.. (3/6/18). "Press Release: LpD64 Acts on Alterations of the Microbiota Involved in the Development of Obesity". La Rochelle....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top